Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Psoriasis (Oct 2020)

Trends That Matter for CAR-T Therapies

Radar On Market Access: Racial Disparities Are Highlighted by Pandemic

Radar On Market Access: Average MA Star Ratings Fall Due to Increased Weights, Cut Points

MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2020)

Perspectives on Provider Consolidation

Radar On Market Access: Trump's $200 Medicare Drug Card Proposal Prompts Criticism

Radar On Market Access: CVS, OptumRx Exclude Brand-Name Inhalers From 2021 Formularies, Switch Up Diabetes Supplies

MMIT Reality Check on IBS-C (Oct 2020)

Trends That Matter on Trump Administration's Rebate Order

Radar On Market Access: COVID-19 Pandemic May Lower Health Care Costs, But Deferral Impact Exists

Radar On Market Access: If Preexisting Condition Protections Vanish, Health Insurers Probably Won't Cheer

MMIT Reality Check on Merkel Cell Carcinoma (Oct 2020)

Perspectives on Amazon-Sharp HealthCare Deal

Radar On Market Access: New Manufacturing Approach May Drive Down CAR-T Therapies' Prices

Radar On Market Access: Experts Remain Skeptical That SCOTUS Will Scuttle Entire ACA

MMIT Reality Check on Sickle Cell Disease (Sep 2020)

Trends That Matter for COVID Cost-Sharing Waivers

Radar On Market Access: Pandemic, Market Stability Encourage Major Insurers to Expand ACA Footprints

Radar On Market Access: As Payer M&A Slows Down, What's Next?

MMIT Reality Check on Schizophrenia (Sep 2020)

Perspectives on PBM Performance Amid COVID-19

Radar On Market Access: Prime Therapeutics Introduces Real Time Benefit Tool

Radar On Market Access: Trump's International Drug Pricing Order Is Still Missing; Rebate Order Draws Fire

MMIT Reality Check on Acute Migraine (Sep 2020)

Trends That Matter for Large Employers in 2021

Radar On Market Access: Amazon Moves Further Into Health Care Data, Sharp Deal Shows

Radar On Market Access: Some COVID Cost-Sharing Waivers Would Expire Soon

MMIT Reality Check on Breast Cancer HR+/HER2- (Sep 2020)

Perspectives on Telehealth Executive Order

Radar On Market Access: Insurers Expand Flu Vaccination Outreach to Blunt COVID-19 Effects

Radar On Market Access: USPS Delivery Slowdown Is Unlikely to Cause Major Rx Fill Disruption

MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (Aug 2020)

Trends That Matter for Prostate Cancer Treatments

Radar On Market Access: Payers Face Challenges to Enroll Newly Uninsured

Radar On Market Access: Large Employers Expect Cost Uncertainty, More Virtual Care in 2021

MMIT Reality Check on Ulcerative Colitis (Aug 2020)

Perspectives on UnitedHealth, Humana's Chronic Conditions Programs

Radar On Market Access: COVID-19 Pandemic Amps Up Interest in Home Care

Radar On Market Access: Anthem, Cigna, CVS Report Strong PBM Performance Amid COVID-19

MMIT Reality Check on Duchenne Muscular Dystrophy (Aug 2020)

Trends That Matter for Major Insurers' Performance Amid COVID-19

Radar On Market Access: Trump Administration Issues Telehealth Executive Order, More Acts Are Needed

Radar On Market Access: FDA Approved Two PARP Inhibitors for Prostate Cancer

MMIT Reality Check on Parkinson's Disease (Aug 2020)

Perspectives on Remdesivir's $3,120 Price Tag

Radar On Market Access: Anthem Warns of Greater Commercial Enrollment Drop in Second Half

Radar On Market Access: Experts Are Skeptical of Trump Administration's Drug Pricing Executive Orders

MMIT Reality Check on Kidney Cancer (July 2020)

Trends That Matter for Medicaid MCOs

Radar On Market Access: UnitedHealth, Humana Launch Programs for Chronic Conditions

Radar On Market Access: Manufacturers, Payers Wait on Federal COVID-19 Vaccine Distribution Plan

MMIT Reality Check on Bipolar Disorder (July 2020)

Perspectives on Trump Admin's COVID-19 Testing Payment Guidance

Radar On Market Access: Despite Coronavirus Surge, UnitedHealth Expects Care Utilization to Rebound This Year

Radar On Market Access: Trump Admin's COVID-19 Testing Payment Guidance Stirs Debate

MMIT Reality Check on Psoriatic Arthritis (July 2020)

Trends That Matter for Racial Disparities in MA Plans

Radar On Market Access: IngenioRx Acquires ZipDrug to Improve Medication Adherence, Affordability

Radar On Market Access: Remdesivir's $3,120 Price Tag Stirs Debate

MMIT Reality Check on Acute Lymphoblastic Leukemia (July 2020)

Perspectives on MedImpact’s New Program to Accelerate Pharmacogenomics

Radar On Market Access: Upheld Transparency Rule Is Slated to Reshape Payer-Provider Negotiations

Radar On Market Access: Reports Show Medicaid MCOs Are 'Dominant,' Increase Affordability

MMIT Reality Check on Hemophilia A or B With Inhibitors (July 2020)

Trends That Matter for DMD Therapies

Radar On Market Access: Insurers Are Required to Cover Only 'Medically Necessary' COVID-19 Tests

Radar On Market Access: CMS Proposes New Medicaid Best Price Rules for Pricey Therapies

MMIT Reality Check on Ankylosing Spondylitis (June 2020)

Perspectives on COVID-19 Vaccine Rollout

Radar On Market Access: Telehealth Regulation and Reimbursement Issue Sparks Debates

Radar On Market Access: CMS Report Shows Increasing Racial Disparities in MA Plans

MMIT Reality Check on Urothelial/Bladder Cancer (June 2020)

Trends That Matter: Enrollment Shift Into ACA Exchanges

Radar On Market Access: Pricey Treatments Face Challenges on Cost Sharing and Data Analysis

Radar On Market Access: MedImpact’s New Program Aims to Accelerate Pharmacogenomics

MMIT Reality Check on Endometriosis (June 2020)

Perspectives on ACA Exchanges Amid COVID-19

Radar On Market Access: Uncertainties Over Effectiveness and High Costs Surround DMD Therapies

Radar On Market Access: 2021 MA, Part D Bids Face Challenges Amid COVID-19

MMIT Reality Check on Chronic Idiopathic Constipation (June 2020)

Trends That Matter: The Future of Value-Based Agreements

Radar On Market Access: 1.7K Plans Apply for Trump Admin's Fixed-Insulin-Copay Program for Seniors

Radar On Market Access: Payers and PBMs May Play Key Role in COVID-19 Vaccine Rollout

MMIT Reality Check on Narcolepsy (May 2020)

Perspectives on Surge of Mental Health Meds Use Amid COVID-19

Radar On Market Access: Will COVID-19 Advance Automatic Health Insurance Enrollment?

Radar On Market Access: COVID-19 Pandemic May Change Rx Delivery Permanently

MMIT Reality Check on Low Testosterone (May 2020)

Trends That Matter for Medical-Benefit Drug Spending

Radar On Market Access: COVID-19 Pandemic Drives Home Infusion Utilization

Radar On Market Access: PBMs See Solid 1Q Results Despite Challenges Ahead

MMIT Reality Check on Pain Narcotic Opioid (May 2020)

Perspectives on Coronavirus Antibody Testing

Radar On Market Access: COVID-19 May Drive More Insurers Into ACA Exchanges

Radar On Market Access: CVS Sees COVID Testing Sites as Part of Bigger HealthHUB Strategy

MMIT Reality Check on Anemia — Chronic Kidney Disease (May 2020)

Trends That Matter for Biosimilar Medications Cost Savings

Radar On Market Access: Anthem, Cigna Brace for Recession-Induced Enrollment Shift

Radar On Market Access: Humana, Centene Maintain 2020 Earnings Outlook Amid COVID-19 Pandemic

MMIT Reality Check on Ophthalmic Anti-Inflammatory (Apr 2020)

Perspectives on ACA and Medicaid Enrollment Growth Amid COVID-19

Radar On Market Access: Oncology Drugs Drive Price Growth in Medical-Benefit Spend

Radar On Market Access: PBMs Say Use of Mental Health Meds Surges Amid COVID-19

MMIT Reality Check on Juvenile Idiopathic Arthritis (Apr 2020)

Trends That Matter for Bipolar Disorder Medications

Radar On Market Access: Medicaid MCOs Are Likely to See COVID-Related Enrollment Growth

Radar On Market Access: Insurers Are Now Required to Cover Coronavirus Antibody Testing

MMIT Reality Check on Acute Myeloid Leukemia (Apr 2020)

Perspectives on COVID-19 Outbreak's Impact on Drug Supply

Radar On Market Access: Slow Biosimilar Adoption and Opaque Markets Impede Potential Savings

Radar On Market Access: PBMs Use Dispensing Limits to Halt Hoarding of Trump-Touted Malaria Drugs

MMIT Reality Check on Opioid Dependence (Apr 2020)

Trends That Matter for Cost Impact of Coronavirus Treatment

Radar On Market Access: Amid COVID-19 Outbreak, CMS Relaxes Rules on MA Data Collection

MMIT Reality Check on COPD (Apr 2020)

Perspectives on New Generic HIV Drug

Radar On Market Access: Congress Could Pass Medicare Part D Reform Even Amid COVID-19 Outbreak

MMIT Reality Check on Glaucoma (Mar 2020)

Trends That Matter for Asthma Medications

Radar On Market Access: ACA Plans and Medicaid May See Enrollment Growth Amid COVID-19 Pandemic

Radar On Market Access: Questions Remain About Cost Impact of Coronavirus Treatment

MMIT Reality Check on Major Depressive Disorder (Mar 2020)

Perspectives on Legality of Closed Medicaid Formularies

Radar On Market Access: COVID-19 Outbreak Could Impact Drug Supply Long-Term

Radar On Market Access: Insurers, Pharma Spar Over Copay Accumulator Provision

MMIT Reality Check on Hereditary Angioedema (Mar 2020)

Trends That Matter for Diabetes Drug Costs

Radar On Market Access: Insurers Deploy Array of Strategies to Manage Asthma

Radar On Market Access: Florida Saw Strong MA, Individual Results and More Consolidations

MMIT Reality Check on HIV (Mar 2020)

Perspectives on ACA Exchange Draft Regulation

Radar On Market Access: New Generic HIV Drug May Impact PrEP Coverage, Not HIV Coverage

Radar On Market Access: Tenn. Blues’ White Bagging Policy Sees Pushback from Providers

MMIT Reality Check on Rheumatoid Arthritis (Feb 2020)

Trends That Matter for Nebraska Medicaid Expansion

Radar on Market Access: Future of Medicaid Work Requirements Dims After Arkansas Demo Is Struck Down Again

Radar On Market Access: CVS Touts Aetna’s Contribution; Molina Exchange Business Stumbles

MMIT Reality Check on Type 2 Diabetes (GLP-1 and Combo) (Feb 2020)

Perspectives on Part D Reform in 2020

Radar On Market Access: Payers Try New Strategies to Control Diabetes Drug Costs

Radar On Market Access: Some Experts Question Legality of Closed Medicaid Formularies

MMIT Reality Check on Neutropenia (Feb 2020)

Trends That Matter for Kansas Medicaid Expansion

Radar On Market Access: ACA Exchange Draft Regulation Drops

Radar On Market Access: New Oncology Biosimilar Launches Could Prompt Preferencing

MMIT Reality Check on Multiple Sclerosis (Feb 2020)

Perspectives on Consolidated PBMs in 2020

Radar On Market Access: Sanofi Backs Away From U.S. PCSK9 Market, While Novartis Bets Big With Inclisiran

Radar on Market Access: Nebraska Proposes A Two-Tiered Medicaid Expansion

MMIT Reality Check on Immune Globulin (PID) (Jan 2020)

Radar on Market Access: Disappointing MCOs, Supreme Court Won't Expedite Obamacare Decision

Radar on Market Access: Could Part D Reform Move Forward in 2020?

MMIT Reality Check on Epilepsy (Jan 2020)

Perspectives on MA Supplemental Benefits

Radar on Market Access: Supreme Court to Determine States' Ability to Regulate PBMs

Radar on Market Access: Kansas Works Out Medicaid Expansion Deal

MMIT Reality Check on Prostate Cancer (Jan 2020)

Trends That Matter for New Multiple Sclerosis Value-Based Contract

Radar on Market Access: State Lawmakers Tee Up Bills on PBMs, Drug Pricing This Year

Radar On Market Access: 2020 Could Be 'Wild Year' for Consolidated PBMs

MMIT Reality Check on Cystic Fibrosis (Jan 2020)

Perspectives on UnitedHealth/Diplomat Deal

Radar On Market Access: Health Care Deals May Slow in 2020, but Government Markets Remain Hot

Radar On Market Access: Navajo Nation, Molina Partner on Medicaid Managed Care in New Mexico

MMIT Reality Check on Growth Hormone Deficiency (Jan 2020)

Trends That Matter for New Acute Migraine Medications

MMIT Reality Check on Ovarian Cancer (Dec 2019)

Perspectives on Dual Eligible SNPs

Radar On Market Access: Health Insurers Receive Multiple Gifts In Year-End Spending Package

Radar On Market Access: Uptake of New MA Supplemental Benefits Remains Modest in 2020, Report Says

Trends That Matter for New Sickle Cell Medications

Radar On Market Access: New Sickle Cell Medications Offer Both Opportunities and Challenges

MMIT Reality Check on Migraine (Dec 2019)

Trends That Matter for Anti-VEGF Market

Radar On Market Access: Patient-Reported Outcomes Play Key Role in New Multiple Sclerosis Value-Based Contract

Radar On Market Access: UnitedHealth Makes Deal to Buy Diplomat as Industry Consolidation Enters 'Second Phase'

MMIT Reality Check on Multiple Myeloma (Dec 2019)

Perspectives on Preferred Cost-Sharing Pharmacy Networks

Radar On Market Access: CMS Struggles With New Medicare Plan Finder 'Glitches'

Radar On Market Access: Highmark's New Hemophilia Initiative Aims to Improve Care, Reduce Costs

MMIT Reality Check on Chronic Lymphocyctic Leukemia (Dec 2019)

Trends That Matter for New Cystic Fibrosis Medication

Radar On Market Access: New Acute Migraine Medications May Not Shake Up Formularies

Radar On Market Access: Amid Budget Standoff, North Carolina Delays Medicaid Transformation

MMIT Reality Check on Crohn's Disease (Nov 2019)

Perspectives on Racial Bias in Optum Risk-Prediction Algorithm

Radar On Market Access: Trump Administration's Transparency Rules Are Part of Larger Effort

Radar On Market Access: National and Regional Players Make Dual Eligible SNP Moves

MMIT Reality Check on Atopic Dermatitis (Nov 2019)

Trends That Matter for 2020 Star Quality Ratings

Radar On Market Access: CVS Health, Cigna Tout Benefits of PBM-Insurer Integration

Radar On Market Access: Independent Pharmacies Push Bill to Increase Access to Part D Preferred Networks

MMIT Reality Check on Immune Globulin (CIDP) (Nov 2019)

Perspectives on How Drug Pricing Legislation Impacts Innovation

Radar On Market Access: 'Breakthrough' Cystic Fibrosis Drug Could See High Demand

Radar On Market Access: Analysts Question Issues Surrounding Beovu's Uptake in Full Anti-VEGF Market

MMIT Reality Check on Uveitis (Nov 2019)

Trends That Matter for IL-17 Use in Psoriasis

Radar On Market Access: Some Insurers Cover Acupuncture to Combat Opioid Epidemic